Skip to main content
. 2021 Mar 29;2021(3):CD001689. doi: 10.1002/14651858.CD001689.pub4

Comparison 14. Sensitivity analysis: antenatal (± postnatal) prophylaxis with heparin versus no treatment/placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
14.1 Symptomatic thromboembolic events 4 476 Risk Ratio (M‐H, Fixed, 95% CI) 0.39 [0.08, 1.98]
14.2 Symptomatic pulmonary embolism 3 187 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.02, 7.14]
14.3 Symptomatic deep vein thrombosis 3 187 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 7.93]